Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tedatioxetine
- Development stage
- Discontinued
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tedatioxetine (Lu AA24530) is an experimental multimodal antidepressant that was developed by Lundbeck and Takeda. It acts as a triple reuptake inhibitor (TRI), inhibiting the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). Additionally, it functions as an antagonist at 5-HT3 and 5-HT2C receptors and as a partial agonist at 5-HT1A receptors. The compound was primarily investigated for the treatment of major depressive disorder (MDD). Despite reaching Phase II and Phase III clinical trials, development was discontinued in 2013-2014 as the clinical data did not support further progression relative to other pipeline candidates like vortioxetine.
- Other names
- tedatioxetineLu AA24530
02
Targets
SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)HTR2C (5-hydroxytryptamine 2C receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ADRA1A (α1A)HTR3A (5-hydroxytryptamine receptor 3A)NET (Norepinephrine Transporter)HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on tedatioxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tedatioxetine.